Skip to main content

Table 3 Multivariate analysis of prognostic factors in ovarian cancer (n = 56)

From: The feasibility and clinical effects of dendritic cell-based immunotherapy targeting synthesized peptides for recurrent ovarian cancer

Variable

 

Log-rank

Wilcoxon

Cox’s hazard regression

    

Hazard ratio

95% CI

P value

Hemoglobin (g/dL)

≥11

0.131

0.165

1

0.524-5.356

0.385

 

<11

  

1.675

  

Albumin (g/dL)

≥4.0

0.017

0.022

1

1.055-11.34

0.04

 

<4.0

  

3.459

  

LDH (IU/L)

≥200

0.107

0.131

1

0.077-0.975

0.046

 

<200

  

0.274

  

CRP (mg/dL)

<0.5

0.009

0.01

1

0.757-13.47

0.114

 

≥0.5

  

3.192

  

Lymphocytes (/μL)

≥1,200

0.688

0.499

1

0.66-7.527

0.197

 

<1,200

  

2.229

  

Neutrophil (/μL)

<4,000

0.766

0.853

1

0.291-4.046

0.903

 

≥4,000

  

1.085

  

Peritoneal metastasis

Yes

0.273

0.483

1

0.137-1.038

0.059

 

No

  

0.378

  

Liver metastasis

Yes

0.795

0.603

1

0.236-5.759

0.851

 

No

  

1.165

  

Ascites

Yes

0.388

0.277

1

0.593-4.84

0.325

 

No

  

1.694

  

Fever after DC vaccine (°C)

<38

0.657

0.72

1

0.235-3.549

0.896

 

≥38

  

0.913

  

Erythema (mm)

≥30

0.083

0.014

1

0.647-7.73

0.203

 

<30

  

2.236

  

WT1 peptide

Yes

0.959

0.608

1

0.388-13.65

0.359

 

No

  

2.3

  

MUC1 peptide

Yes

0.479

0.59

1

0.324-2.752

0.917

 

No

  

0.945

  
Back to article page

Journal of Ovarian Research

ISSN: 1757-2215

Contact us